DE602006008643D1 - Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie - Google Patents

Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie

Info

Publication number
DE602006008643D1
DE602006008643D1 DE602006008643T DE602006008643T DE602006008643D1 DE 602006008643 D1 DE602006008643 D1 DE 602006008643D1 DE 602006008643 T DE602006008643 T DE 602006008643T DE 602006008643 T DE602006008643 T DE 602006008643T DE 602006008643 D1 DE602006008643 D1 DE 602006008643D1
Authority
DE
Germany
Prior art keywords
presbyopia
inflammatories
treatment
ophthalmic compositions
parasympathetic stimulants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006008643T
Other languages
English (en)
Inventor
Jorge Luis Benozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE602006008643D1 publication Critical patent/DE602006008643D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006008643T 2006-12-18 2006-12-18 Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie Active DE602006008643D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026169A EP1938839B1 (de) 2006-12-18 2006-12-18 Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie

Publications (1)

Publication Number Publication Date
DE602006008643D1 true DE602006008643D1 (de) 2009-10-01

Family

ID=37969963

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006008643T Active DE602006008643D1 (de) 2006-12-18 2006-12-18 Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie

Country Status (13)

Country Link
US (2) US8524758B2 (de)
EP (1) EP1938839B1 (de)
JP (1) JP5769375B2 (de)
AT (1) ATE439863T1 (de)
AU (1) AU2007335919B2 (de)
BR (1) BRPI0720355B8 (de)
CA (1) CA2672985C (de)
DE (1) DE602006008643D1 (de)
DK (1) DK1938839T3 (de)
ES (1) ES2329161T3 (de)
MX (1) MX2009006505A (de)
PT (1) PT1938839E (de)
WO (1) WO2008075149A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
DK2758047T3 (en) 2011-09-20 2019-04-01 Allergan Inc COMPOSITIONS AND PROCEDURES FOR TREATING PRESBYOPY, MILD HYPEROPY AND IRREGULAR ASTIGMATISM
WO2013126838A2 (en) * 2012-02-25 2013-08-29 Thrufocus Optics, Inc. Devices and methods for improving vision using laser photomiosis
US10744034B2 (en) * 2012-04-25 2020-08-18 Gregg S. Homer Method for laser treatment for glaucoma
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN106061490A (zh) * 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
CN106456584A (zh) * 2014-02-11 2017-02-22 阿拉西斯医药公司 用于矫正老视的药理学眼科用组合物和其施用
CN116808032A (zh) 2015-06-18 2023-09-29 伦茨治疗股份有限公司 储存稳定的组合物以及治疗眼睛屈光不正的方法
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
US10406352B2 (en) * 2016-10-13 2019-09-10 Ronald Michael Kurtz System for temporary nonpharmacologic constriction of the pupil
US20180104099A1 (en) * 2016-10-13 2018-04-19 Ronald Michael Kurtz Digitally controlled optical system for nonpharmacologic constriction of a pupil
US20180104508A1 (en) * 2016-10-13 2018-04-19 Ronald Michael Kurtz Optical system for nonpharmacologic constriction of a pupil
US20180104098A1 (en) * 2016-10-13 2018-04-19 Ronald Michael Kurtz System for nonpharmacologic long-term constriction of a pupil
US10406380B2 (en) * 2016-10-13 2019-09-10 Ronald Michael Kurtz Method for nonpharmacologic temporary constriction of a pupil
LT3681500T (lt) * 2018-04-24 2022-06-27 Allergan, Inc. Pilokarpino hidrochlorido naudojimas presbiopijos gydymui
EP4243798A1 (de) * 2020-11-13 2023-09-20 Plex Pharmaceuticals, Inc. Pharmakologische wirkstoffe zur behandlung von augenleiden
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001096A1 (en) * 1992-07-02 1994-01-20 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6263879B1 (en) * 1998-11-10 2001-07-24 J. T. Lin Treatment of presbyopia and other eye disorders using a scanning laser system
US6258082B1 (en) * 1999-05-03 2001-07-10 J. T. Lin Refractive surgery and presbyopia correction using infrared and ultraviolet lasers
US6540990B2 (en) * 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6273092B1 (en) * 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US20050205101A1 (en) * 2002-10-17 2005-09-22 Lin J T Combined pharmocological and surgical method and system for the treatment of eye disorders
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent

Also Published As

Publication number Publication date
US20100016395A1 (en) 2010-01-21
PT1938839E (pt) 2009-09-30
ATE439863T1 (de) 2009-09-15
BRPI0720355B1 (pt) 2019-02-05
US20130197047A1 (en) 2013-08-01
AU2007335919B2 (en) 2012-11-08
MX2009006505A (es) 2009-09-18
ES2329161T3 (es) 2009-11-23
EP1938839B1 (de) 2009-08-19
WO2008075149A2 (en) 2008-06-26
US8524758B2 (en) 2013-09-03
BRPI0720355B8 (pt) 2023-01-24
EP1938839A1 (de) 2008-07-02
JP5769375B2 (ja) 2015-08-26
BRPI0720355A2 (pt) 2013-12-31
JP2010513454A (ja) 2010-04-30
AU2007335919A1 (en) 2008-06-26
DK1938839T3 (da) 2009-11-30
WO2008075149A3 (en) 2008-08-14
CA2672985A1 (en) 2008-06-26
CA2672985C (en) 2013-06-11

Similar Documents

Publication Publication Date Title
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE521608T1 (de) Glucokinaseaktivatoren
DE502006007963D1 (de) Verwendung von hydrophobinen zur schmutzabweisenden behandlung von harten oberflächen
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE399158T1 (de) Heterocyclische phenylaminopropanolderivate als modulatoren der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
ATE472329T1 (de) Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
ATE479716T1 (de) Copolymerisate und ihre verwendung zur behandlung von flexiblen substraten
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE602006018725D1 (de) Amidin-derivate zur verwendung in der vorbeugung oder behandlung von glaukom

Legal Events

Date Code Title Description
8364 No opposition during term of opposition